MG-T-19
Based on 1 Customer Validation
MG-T-19 is a potent small-molecule inhibitor targeting human TIM-3. MG-T-19 blocks the interactions between TIM-3 and its ligands such as phosphatidylserine, CEACAM1 and Galectin-9. MG-T-19 promotes the secretion of TNF-α and IFN-γ by peripheral blood mononuclear cells, and significantly enhances their ability to inhibit cancer cell proliferation. MG-T-19 can be used in studies related to acute myeloid leukemia.
For research use only. We do not sell to patients.
- Purity : 98.34%
- CAS No.: 328540-44-9
- Formula: C18H8Br2ClF3N4O2S
- Molecular Weight:596.60
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
MG-T-19 (2.5 μM) significantly inhibits the interactions of human TIM-3 with PtdSer, CEACAM1, and Gal-9 in cell-free and cell-based ligand binding assays[1].
MG-T-19 (2.5 μM; 48 h) pretreatment of healthy donor PBMCs increases TNF-α and IFN-γ production following stimulation[1].
MG-T-19 (2.5 μM; 6 days) incubation of Kasumi-1 acute myelogenous leukemia cells with healthy donor PBMCs significantly reduces Kasumi-1 cell proliferation[1].
MG-T-19 binds to purified human TIM-3 with a Kd of 0.26 μM and inhibits TIM-3 interactions with its ligands PtdSer, CEACAM-1, and galectin-9[2].
MG-T-19 enhances TNF-α and IFN-γ secretion by healthy donor peripheral blood mononuclear cells and boosts inhibition of Kasumi-1 cell proliferation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Kasumi-1 acute myelogenous leukemia cells, peripheral blood mononuclear cells (PBMCs) from healthy donors
-
Concentration:2.5 μM
-
Incubation Time:6 days; 16 h (H3 thymidine labeling)
-
Result:Augmented the capacity of PBMCs to impede the proliferation of Kasumi-1 cells, resulting in significantly reduced H3 thymidine uptake compared to coculture controls.
Chemical Information
-
CAS No. 328540-44-9
-
Appearance Solid
-
Molecular Weight 596.60
-
Formula C18H8Br2ClF3N4O2S
-
Color Light yellow to yellow
-
SMILES
OC1=C(NC(C2=NN3C(N=C(C4=CC(Br)=CS4)C=C3C(F)(F)F)=C2Br)=O)C=C(Cl)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 14.29 mg/mL (23.95 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 1.43 mg/mL (2.40 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
This protocol yields a clear solution of 1.43 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (14.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[1]. Abdel-Rahman SA, et al. Small molecules from antibody pharmacophores (SMAbPs) as a hit identification workflow for immune checkpoints. Science advances. 2024 Oct 18;10(42):eadq5540. [Content Brief]
[2]. Wang L, et al. TIM-3 Inhibitor Development: Overcoming Immune Evasion in Cancer Therapy. Journal of medicinal chemistry. 2025 Dec 25;68(24):25754-25771. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6762 mL | 8.3808 mL | 16.7617 mL | 41.9041 mL |
| 5 mM | 0.3352 mL | 1.6762 mL | 3.3523 mL | 8.3808 mL | |
| 10 mM | 0.1676 mL | 0.8381 mL | 1.6762 mL | 4.1904 mL | |
| 15 mM | 0.1117 mL | 0.5587 mL | 1.1174 mL | 2.7936 mL | |
| 20 mM | 0.0838 mL | 0.4190 mL | 0.8381 mL | 2.0952 mL |
MG-T-19 Related Classifications
HY-159884 Related Classifications
Powered by Bioz